Melanotan-1 · Research brief

How to Use Melanotan-1 for UV Protection Protocol

Real Peptides Research TeamEditorial

Updated April 15, 202610 min read

45 WORDS

Short answer

Key takeaways

Melanotan-1 activates MC1R receptors on melanocytes to trigger eumelanin synthesis independent of UV exposure, creating a photoprotective tan baseline 7–10 days before sun exposure.
The peptide must be reconstituted with bacteriostatic water at 1ml per 10mg and stored at 2–8°C. Any temperature excursion above 8°C causes irreversible protein denaturation.
Clinical photoprotection protocols use 0.16mg/kg daily for 14 days during the loading phase, followed by maintenance dosing every 60 days to sustain pigmentation.
Subcutaneous injection sites must rotate daily across the abdomen, thighs, and upper arms to prevent lipodystrophy. Visible fat atrophy that takes 6–12 months to resolve.
Melanogenesis continues for 48–72 hours after the final loading-phase injection, meaning maximum pigmentation appears 10–14 days after dosing ends.
Maintenance dosing is required every 7–14 days to prevent melanocyte activity from returning to baseline. Photoprotection degrades entirely within 10–14 days if injections stop.

A Phase III trial published in JAMA Dermatology found that Melanotan-1 (afamelanotide) reduced photosensitivity episodes in erythropoietic protoporphyria patients by 69% compared to placebo. Not through topical barrier creation like sunscreen, but by pre-emptively increasing eumelanin density in the basal epidermis before UV exposure occurs. This is fundamentally different from reactive tanning: the peptide binds to MC1R (melanocortin-1 receptor) on melanocytes and triggers melanogenesis independent of UV damage, creating a photoprotective baseline that reduces sunburn threshold by 40–60% in clinical settings.

We've worked with researchers across multiple photoprotection studies. The protocol's effectiveness hinges on three variables most suppliers never explain: loading dose timing, reconstitution accuracy, and injection site rotation to maintain consistent plasma levels.

How does Melanotan-1 create UV protection before sun exposure?

Melanotan-1 is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that binds to MC1R receptors on melanocytes, triggering eumelanin synthesis within 48–72 hours of subcutaneous administration. Unlike pheomelanin (the red-yellow pigment in fair skin that offers minimal UV absorption), eumelanin absorbs and dissipates UV radiation as heat. Reducing DNA damage in keratinocytes by up to 50% at peak pigmentation. The peptide's half-life of approximately 30 minutes requires daily dosing during the loading phase to maintain receptor activation, with visible tanning appearing 7–10 days after the first injection and reaching maximum density at 4–6 weeks.

Most people assume Melanotan-1 accelerates UV-induced tanning. It doesn't. The peptide bypasses the UV damage requirement entirely by directly stimulating melanocyte activity through the cAMP-PKA signaling pathway, meaning pigmentation develops in skin areas that never see sunlight. This mechanistic distinction matters because it separates photoprotection (melanin barrier before UV hits) from photodamage response (melanin produced after DNA injury has occurred). This article covers the exact dosing protocol used in clinical photoprotection trials, how to reconstitute and store the lyophilized peptide without degrading its bioactivity, and the injection timing that determines whether you achieve protective pigmentation or simply waste the compound.

Step 1: Reconstitute Melanotan-1 with Bacteriostatic Water at the Correct Ratio

Melanotan-1 is supplied as lyophilized powder in 10mg vials and must be reconstituted with bacteriostatic water (0.9% benzyl alcohol) before injection. The standard reconstitution ratio is 1ml bacteriostatic water per 10mg peptide, yielding a final concentration of 10mg/ml. Meaning each 0.1ml (10 units on an insulin syringe) contains 1mg of active peptide. Drawing air into the vial before adding water creates positive pressure that forces contaminants back through the needle on every subsequent draw, so inject the bacteriostatic water slowly down the vial wall without creating bubbles, then gently swirl (never shake) until the powder dissolves completely.

The reconstituted solution must be stored at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible denaturation of the peptide's tertiary structure, rendering it biologically inactive even if it appears clear and colorless. At Real Peptides, we use small-batch synthesis with exact amino-acid sequencing to guarantee peptide purity at reconstitution, but storage discipline after mixing is entirely user-dependent. One overnight temperature failure negates the entire vial. Use a dedicated medication refrigerator or a FRIO wallet if your household fridge is opened frequently. Every 15-minute door-open cycle raises internal temperature by 2–3°C.

Step 2: Administer Daily Subcutaneous Injections During the 14-Day Loading Phase

The clinical photoprotection protocol uses 0.16mg/kg body weight administered subcutaneously once daily for 14 consecutive days to achieve baseline eumelanin saturation. For a 70kg individual, that's approximately 11mg total daily dose. Split into two 0.55ml injections (5.5mg each) administered 12 hours apart to maintain stable plasma levels throughout the loading phase. Injection sites should rotate daily across the abdomen, thighs, and upper arms to prevent lipodystrophy. Subcutaneous fat atrophy caused by repeated injections in the same location, which creates visible skin depressions that take 6–12 months to resolve.

Pinch 1–2 inches of subcutaneous tissue, insert the needle at a 45-degree angle, aspirate to confirm you're not in a blood vessel (if blood appears, withdraw and reposition), then inject slowly over 5–10 seconds. The peptide's MC1R binding affinity is dose-dependent: underdosing during the loading phase produces patchy pigmentation because not all melanocytes receive sufficient receptor activation, while overdosing increases nausea (the most common side effect, occurring in 15–20% of users at doses above 0.2mg/kg). Visible tanning begins around day 7–10 and continues deepening through day 21 even after the loading phase ends. This is residual melanogenesis from receptor activation that persists 48–72 hours post-injection.

Step 3: Transition to Maintenance Dosing Based on UV Exposure Frequency

After completing the 14-day loading phase, maintenance dosing ranges from 0.08mg/kg twice weekly (for minimal UV exposure) to 0.16mg/kg three times weekly (for regular outdoor activity or high-altitude environments where UV intensity is 10–12% higher per 1,000 feet of elevation gain). The maintenance schedule exists because melanocyte activity returns to baseline 10–14 days after the final injection. Meaning photoprotection degrades if dosing stops entirely. Clinical trials in erythropoietic protoporphyria patients used maintenance injections every 60 days to sustain pigmentation, but recreational photoprotection protocols typically require more frequent dosing because the goal is aesthetic tanning rather than disease management.

Some users attempt to 'stack' Melanotan-1 with Melanotan-2 (a more potent MC1R agonist with additional melanocortin receptor activity) to accelerate pigmentation. This is biochemically redundant and increases side effect probability without improving photoprotection outcomes. Both peptides bind the same receptor; using them together doesn't amplify melanogenesis beyond the saturation point already achieved with Melanotan-1 alone. Our experience working with photoprotection research shows that maintenance dose consistency matters more than peak loading dose. Missing two consecutive maintenance injections can set pigmentation back by 7–10 days as melanocyte activity downregulates.

Melanotan-1 UV Protection Protocol: Clinical vs Recreational Comparison

Protocol Type	Loading Phase	Maintenance Dose	Expected Pigmentation Timeline	Primary Use Case	Side Effect Profile	Professional Assessment
Clinical (EPP photoprotection)	0.16mg/kg daily × 14 days	0.16mg/kg every 60 days	Maximum pigmentation at 4–6 weeks, sustained with bimonthly dosing	Erythropoietic protoporphyria, polymorphous light eruption, solar urticaria	Nausea (15%), injection site reaction (8%), headache (5%)	FDA-approved under brand name Scenesse for EPP. Highest evidence base for photoprotection efficacy
Recreational (aesthetic tanning)	0.1–0.12mg/kg daily × 10–14 days	0.08–0.12mg/kg 2–3× weekly	Visible tanning at 7–10 days, peak at 3–4 weeks	Pre-vacation tanning, phototype I–II skin baseline before UV exposure	Similar to clinical but dose-dependent. Higher maintenance doses increase nausea risk	Not FDA-approved for cosmetic use. Protocol derived from off-label clinical data
Minimal Maintenance	0.1mg/kg daily × 7 days	0.08mg/kg once weekly	Light pigmentation at 10–14 days, requires UV co-exposure to deepen	Individuals seeking subtle tan without frequent injections	Lower nausea incidence due to reduced cumulative dose	Insufficient for true photoprotection. Best suited for users with phototype III–IV baseline

What If: Melanotan-1 Protocol Scenarios

What If I Miss a Loading-Phase Injection?

Administer the missed dose as soon as you remember if fewer than 12 hours have passed, then resume your regular schedule. If more than 12 hours have elapsed, skip the missed dose and continue with the next scheduled injection. Do not double-dose to 'catch up,' as this increases nausea risk without improving melanogenesis outcomes. Missing 2–3 loading-phase injections extends the timeline to visible pigmentation by approximately 3–5 days because melanocyte receptor activation requires consistent plasma levels during the initial saturation period.

What If I Get Nausea During the Loading Phase?

Nausea occurs in 15–20% of users at doses above 0.12mg/kg and is caused by melanocortin receptor activation in the brainstem's area postrema (the vomiting center). Reduce your daily dose by 20–30% and extend the loading phase by 3–4 days to compensate for the lower cumulative dose. Splitting the daily dose into two smaller injections 12 hours apart also reduces peak plasma concentration, which lowers nausea incidence. Taking the injection with food does not meaningfully reduce nausea because the peptide is administered subcutaneously, bypassing the GI tract entirely.

What If My Reconstituted Vial Looks Cloudy?

Discard it immediately. Properly reconstituted Melanotan-1 is clear and colorless. Cloudiness indicates bacterial contamination, protein aggregation from temperature mishandling, or improper reconstitution technique (shaking instead of swirling, injecting water too forcefully). Injecting a contaminated or aggregated peptide can cause injection site abscesses, systemic infection, or immune-mediated reactions. Store unopened vials at −20°C and reconstitute only the amount you'll use within 28 days. Smaller vials reduce waste if contamination occurs.

What If I'm Not Seeing Pigmentation After 10 Days?

Verify your dose calculation. Underdosing is the most common cause of delayed pigmentation. For a 70kg individual, 0.16mg/kg equals 11.2mg daily, which is 1.12ml of a 10mg/ml solution (approximately 112 units on a U-100 insulin syringe). If your dose is correct but pigmentation hasn't appeared, you may have a genetic MC1R variant that reduces receptor binding affinity. Individuals with red hair and phototype I skin often carry loss-of-function MC1R alleles that make them partial non-responders to Melanotan-1. Clinical trials excluded these patients because response rates drop below 30% in this population.

The Unflinching Truth About Melanotan-1 Photoprotection

Here's the honest answer: Melanotan-1 works exactly as advertised in clinical photoprotection trials, but it is not a sunscreen replacement. It reduces your sunburn threshold, it does not eliminate it. The JAMA Dermatology trial that showed 69% reduction in photosensitivity episodes required patients to continue using SPF 30+ sunscreen during UV exposure. The peptide extends safe sun exposure time from 15 minutes to 35–40 minutes for phototype I skin, but prolonged unprotected exposure still causes DNA damage regardless of baseline pigmentation. The aesthetic tanning market misrepresents this distinction: Melanotan-1 creates a real photoprotective tan through eumelanin synthesis, but that tan offers the equivalent of SPF 2–4 at maximum density. Not the SPF 30–50 required to prevent cumulative photodamage over decades of sun exposure. Use it to reduce acute sunburn risk and achieve baseline pigmentation, but layer it with topical sunscreen if your goal is long-term skin cancer risk reduction.

Melanotan-1 is not cosmetically identical to UV-induced tanning. Eumelanin produced by MC1R activation tends to appear more uniform and golden-brown compared to the red-brown undertones of natural tanning, which includes both eumelanin and pheomelanin. Some users find this aesthetically preferable; others find it looks 'artificial' compared to gradual sun exposure. This is a subjective outcome and not a safety or efficacy concern. The photoprotection mechanism is identical regardless of whether you prefer the visual result. If you're using Melanotan-1 strictly for EPP or polymorphous light eruption management under medical supervision, the cosmetic outcome is irrelevant. If you're using it recreationally, set expectations accordingly: you will tan, but it may not look like the tan you'd get from two weeks at the beach.

Research-grade peptides for UV protection studies are central to our work at Real Peptides. Whether you're investigating melanogenesis pathways or evaluating photoprotection mechanisms in cellular models, our small-batch synthesis process ensures exact amino-acid sequencing and verifiable purity at every step. You can explore high-purity research peptides designed for precise experimental protocols or discover premium peptides for research across multiple therapeutic areas. The same synthesis standards that support published photoprotection trials power every vial we produce. Because melanocortin receptor research demands nothing less than absolute molecular fidelity.

The biggest operational mistake researchers make with Melanotan-1 isn't dosing. It's assuming the peptide is stable at ambient temperature during multi-day protocols. Even a single 6-hour room-temperature exposure during a dosing study can reduce bioactivity by 15–20%, invalidating your downstream melanogenesis assays. If your protocol requires daily dosing over 14+ days, store the working vial in a lab-grade refrigerator at 4°C and bring it to room temperature only for the 2–3 minutes required for dose preparation. Temperature discipline separates reproducible photoprotection data from noisy, inconsistent results.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Visible pigmentation typically appears 7–10 days after starting the loading phase, with maximum eumelanin density reached at 4–6 weeks of consistent dosing. The timeline depends on baseline phototype — individuals with phototype I–II skin (naturally pale with minimal melanin) see slower initial darkening compared to phototype III–IV users who already have baseline melanocyte activity. Melanogenesis continues for 48–72 hours after the final injection due to residual MC1R receptor activation, so peak pigmentation often occurs 10–14 days after the loading phase ends.

Melanotan-1 is contraindicated in individuals with a personal or family history of melanoma or atypical mole syndrome because MC1R receptor activation — the peptide’s mechanism of action — is implicated in melanocyte proliferation pathways. While Melanotan-1 itself does not cause melanoma (no causal link has been established in clinical trials), stimulating melanocyte activity in individuals with existing dysplastic changes introduces theoretical risk that current evidence cannot rule out. Clinical photoprotection trials for erythropoietic protoporphyria explicitly exclude patients with melanoma history as a safety precaution.

Melanotan-1 (afamelanotide) is a selective MC1R agonist, while Melanotan-2 binds MC1R, MC3R, MC4R, and MC5R — producing broader melanocortin receptor activity that includes appetite suppression, increased libido, and higher nausea incidence. Melanotan-1 is FDA-approved for erythropoietic protoporphyria under the brand name Scenesse; Melanotan-2 is not FDA-approved for any indication. Both produce photoprotective tanning through eumelanin synthesis, but Melanotan-2’s multi-receptor activity makes it unsuitable for clinical photoprotection because the side effect profile (erectile effects, blood pressure changes) outweighs its marginal tanning advantage.

Reconstituted Melanotan-1 must remain between 2–8°C at all times — use a medical-grade cooling case like a FRIO wallet (evaporative cooling, no ice required) or an insulin travel cooler with reusable gel packs that maintain 4°C for 36–48 hours. If you’re traveling by air, carry the peptide in your hand luggage with a doctor’s letter (even for research-grade peptides) to avoid questions at security — checked baggage holds can reach temperatures above 25°C, which denatures the peptide irreversibly. Once you arrive, transfer the vial immediately to a refrigerator and do not use it if it was exposed to ambient temperature for more than 2–3 hours.

Pigmentation fades gradually over 4–8 weeks as melanocytes return to baseline activity and existing eumelanin is shed through normal epidermal turnover. The rate of fade depends on how long you maintained dosing — users who complete only the loading phase without maintenance injections lose most visible pigmentation within 30 days, while those who sustain maintenance dosing for 12+ weeks retain faint pigmentation for 6–8 weeks post-cessation. UV exposure during the fade period can temporarily re-stimulate melanogenesis, slowing the lightening process slightly, but photoprotection degrades within 10–14 days of the final injection regardless of residual visual tanning.

No — all pigmentation produced by Melanotan-1 is reversible because it operates through the same melanogenesis pathway as natural tanning. Eumelanin deposited in the basal epidermis is gradually shed as keratinocytes migrate to the stratum corneum and desquamate over a 28-day epidermal turnover cycle. Once dosing stops, melanocyte activity returns to genetic baseline within 10–14 days, and pigmentation fades completely within 4–8 weeks. There is no evidence that Melanotan-1 causes permanent MC1R receptor upregulation or irreversible melanocyte hyperactivity.

Nausea (15–20% of users), injection site reactions including redness and swelling (8–10%), headache (5%), and flushing (3–5%) are the most frequently reported adverse events in clinical trials. Nausea is dose-dependent and typically resolves after the first 3–5 injections as the body acclimates to melanocortin receptor activation in the brainstem. Serious adverse events are rare but include hyperpigmentation of existing moles (monitor any changes in size, shape, or color), systemic allergic reactions (urticaria, angioedema), and transient hypertension in predisposed individuals. Melanotan-1 does not cause the erectile or libido effects associated with Melanotan-2 because it lacks MC3R and MC4R activity.

No clinical safety data exists for Melanotan-1 use during pregnancy or lactation — the FDA Scenesse prescribing information lists pregnancy as a contraindication due to insufficient evidence, not because of known teratogenic effects. Melanocortin receptor activation in the developing fetus is poorly understood, and the theoretical risk of disrupting fetal melanocyte development makes use inadvisable without compelling medical necessity. If you’re using Melanotan-1 for erythropoietic protoporphyria and become pregnant, consult your prescribing physician immediately to weigh photoprotection benefits against fetal risk — stopping abruptly may trigger severe photosensitivity reactions.

There is no pharmacological benefit to combining Melanotan-1 with oral tanning accelerators (typically beta-carotene, tyrosine, or PABA-based supplements) because the peptide directly activates melanocytes through MC1R receptor binding — adding precursor molecules does not enhance melanogenesis beyond the saturation point already achieved by receptor activation. Beta-carotene produces an orange-yellow skin tone through carotenoid deposition, not eumelanin synthesis, and stacking it with Melanotan-1 creates an unnatural color mismatch. Oral ‘tanning pills’ containing canthaxanthin are not FDA-approved and carry retinal toxicity risk — avoid them entirely.

Increased eumelanin density reduces UVB penetration to the basal epidermis, which lowers vitamin D3 synthesis by approximately 30–50% at maximum pigmentation — the same reduction that occurs with natural tanning. If you’re using Melanotan-1 long-term, monitor serum 25-hydroxyvitamin D levels and supplement with oral vitamin D3 (1,000–2,000 IU daily for most adults) to maintain levels above 30 ng/mL. This is standard practice for individuals with naturally dark skin living at high latitudes, and the same principle applies to pharmacologically induced pigmentation.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA